From gene panel testing to new molecularly targeted therapy.
作者信息
Matsumura Noriomi
机构信息
Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
出版信息
Int Cancer Conf J. 2024 Mar 16;13(2):75. doi: 10.1007/s13691-024-00672-8. eCollection 2024 Apr.
Abstract
摘要
相似文献
1
From gene panel testing to new molecularly targeted therapy.从基因panel检测到新型分子靶向治疗。
Int Cancer Conf J. 2024 Mar 16;13(2):75. doi: 10.1007/s13691-024-00672-8. eCollection 2024 Apr.
2
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.基于肿瘤分子谱的分子靶向治疗与晚期癌症的常规治疗（SHIVA）：一项多中心、开放标签、概念验证、随机、对照的 2 期临床试验。
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
3
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.基因组改变、分子靶向治疗与生存：一项现实世界的子宫内膜癌分子靶向治疗联盟队列研究。
Int J Gynecol Cancer. 2025 May;35(5):101758. doi: 10.1016/j.ijgc.2025.101758. Epub 2025 Apr 7.
4
Resistance to molecularly targeted therapy in non-small-cell lung cancer.非小细胞肺癌对分子靶向治疗的耐药性。
Respir Investig. 2019 Jan;57(1):20-26. doi: 10.1016/j.resinv.2018.09.001. Epub 2018 Oct 4.
5
Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.复发性/晚期妇科癌症多基因检测板检测的临床可用性及特征
Int J Clin Oncol. 2023 Nov;28(11):1554-1562. doi: 10.1007/s10147-023-02398-8. Epub 2023 Aug 13.
6
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.小组规模更小，结果相似：胰腺癌的基因组分析和分子指导治疗。
ESMO Open. 2023 Jun;8(3):101539. doi: 10.1016/j.esmoop.2023.101539. Epub 2023 May 4.
7
Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.临床靶向下一代测序 panel 用于检测脑胶质瘤中的体细胞变异。
Cancer Res Treat. 2020 Jan;52(1):41-50. doi: 10.4143/crt.2019.036. Epub 2019 May 7.
8
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.不可切除肝细胞癌治疗新时代中分子靶向治疗与免疫检查点抑制剂的联合应用
Ther Adv Med Oncol. 2021 May 24;13:17588359211018026. doi: 10.1177/17588359211018026. eCollection 2021.
9
Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?靶向与扩展药物基因组学检测的比较：我们遗漏了什么？
J Am Pharm Assoc (2003). 2023 May-Jun;63(3):939-945. doi: 10.1016/j.japh.2023.02.020. Epub 2023 Mar 2.
10
Identification of barriers to implementation of precision oncology in patients with rare cancers.罕见癌症患者精准肿瘤学实施障碍的识别。
Cancer Sci. 2024 Jun;115(6):2023-2035. doi: 10.1111/cas.16165. Epub 2024 Mar 27.
本文引用的文献
1
Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring amplification.一名起源于胆囊且携带 扩增的神经内分泌癌患者对卡马替尼的反应。
Int Cancer Conf J. 2024 Jan 2;13(2):83-87. doi: 10.1007/s13691-023-00643-5. eCollection 2024 Apr.
Zotero 插件